---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-012993"
form_type: "8-K"
ticker: "SION"
cik: "0002036042"
company_name: "Sionna Therapeutics, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:51:42.743786+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sionna Therapeutics Q4 2025 net loss $20.4M; cash $310.3M funds into 2028

## Summary
- Net loss $20.4M (Q4) and $75.3M (FY 2025) vs $15.8M and $61.7M in 2024.
- Cash and equivalents $310.3M as of Dec 31, 2025; expected to fund operations into 2028.
- Phase 2a PreciSION CF trial of SION-719 on track; topline data expected mid-2026.
- Phase 1 dual combo trial of SION-451 with SION-2222/SION-109 on track; data mid-2026.
- R&D expenses $15.2M (Q4) and $60.3M (FY); G&A expenses $8.4M (Q4) and $28.7M (FY).

## SEC filing metadata
- accession: 0001628280-26-012993
- form_type: 8-K
- ticker: SION
- cik: 0002036042
- company_name: Sionna Therapeutics, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/0001628280-26-012993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/sion-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-012993
- JSON: https://secwatch.observer/filing/0001628280-26-012993.json
- Plain text: https://secwatch.observer/filing/0001628280-26-012993.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.